by mpzzqmvj | Mar 14, 2022 | Press Releases
– Lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) continues to progress – Company advancing Trappsol® Cyclo™ for the treatment of...
by mpzzqmvj | Mar 10, 2022 | Press Releases
Presentation with live video webcast on Wednesday, March 16th at 3:20 PM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to...
by mpzzqmvj | Feb 8, 2022 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Feb 3, 2022 | Press Releases
– Company’s pivotal Phase 3 study, TransportNPC™, ongoing with global site activation and patient enrollment underway – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with...
by mpzzqmvj | Jan 20, 2022 | Press Releases
– Live video webcast presentation on Thursday, January 27th at 10:00 AM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to...
